# RAD001 in Combination With Cetuximab and Cisplatin in Recurrent and Metastatic SCCHN

> **NCT01009346** · PHASE1,PHASE2 · TERMINATED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 9 (actual)

## Conditions studied

- Head and Neck Cancer

## Interventions

- **DRUG:** RAD001
- **DRUG:** Cetuximab
- **DRUG:** Cisplatin
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT01009346
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-10
- **Primary completion:** 2011-03
- **Final completion:** 2011-03
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Toxicity
- **Last updated:** 2018-07-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01009346

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01009346, "RAD001 in Combination With Cetuximab and Cisplatin in Recurrent and Metastatic SCCHN". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01009346. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*